• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Patterns of progression among 427 Smoldering Myeloma patients diagnosed after 2014: importance of monitoring.

作者信息

Kastritis Efstathios, Solia Irene, Malandrakis Panagiotis, Theodorakakou Foteini, Ntanasis-Stathopoulos Ioannis, Kanellias Nikolaos, Fotiou Despina V, Migkou Magdalini, Eleutherakis Papaiakovou Evangelos, Spiliopoulou Vassiliki, Kokkali Nikoletta-Aikaterini, Papanikolaou Asimina, Giannouli Stavroula, Gavriatopoulou Maria, Terpos Evangelos, Dimopoulos Meletios-Athanasios A

机构信息

Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.

NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHEN, ATHENS, Greece.

出版信息

Blood Adv. 2025 Mar 31. doi: 10.1182/bloodadvances.2025016083.

DOI:10.1182/bloodadvances.2025016083
PMID:40163763
Abstract
摘要

相似文献

1
Patterns of progression among 427 Smoldering Myeloma patients diagnosed after 2014: importance of monitoring.2014年后确诊的427例冒烟型骨髓瘤患者的疾病进展模式：监测的重要性
Blood Adv. 2025 Mar 31. doi: 10.1182/bloodadvances.2025016083.
2
Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma.达雷妥尤单抗或高危冒烟型多发性骨髓瘤的主动监测
N Engl J Med. 2025 May 8;392(18):1777-1788. doi: 10.1056/NEJMoa2409029. Epub 2024 Dec 9.
3
Association Between Patient Demographics and Smoldering Multiple Myeloma Progression to Multiple Myeloma: A SEER-Medicare Data Analysis.患者人口统计学特征与冒烟型多发性骨髓瘤进展为多发性骨髓瘤之间的关联：一项监测、流行病学和最终结果（SEER）-医疗保险数据分析
Clin Lymphoma Myeloma Leuk. 2025 Jun 22. doi: 10.1016/j.clml.2025.06.016.
4
Evaluating early intervention in smoldering myeloma clinical trials: a systematic review.评估冒烟型骨髓瘤临床试验中的早期干预：一项系统综述
Oncologist. 2025 Feb 6;30(2). doi: 10.1093/oncolo/oyae219.
5
Immunoglobulin G4 Smoldering Multiple Myeloma With Immunoglobulin G4-Related Autoimmune Hepatitis: A Rare Case Report.伴有免疫球蛋白G4相关自身免疫性肝炎的免疫球蛋白G4冒烟型多发性骨髓瘤：一例罕见病例报告
Immun Inflamm Dis. 2025 Aug;13(8):e70244. doi: 10.1002/iid3.70244.
6
The effect of intervention versus watchful waiting on disease progression and overall survival in smoldering multiple myeloma: a systematic review of randomized controlled trials.干预与观察等待对冒烟型多发性骨髓瘤疾病进展和总生存期的影响：一项随机对照试验的系统评价
J Cancer Res Clin Oncol. 2022 Apr;148(4):897-911. doi: 10.1007/s00432-022-03920-7. Epub 2022 Jan 20.
7
Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma.高危冒烟型骨髓瘤患者免疫治疗反应的免疫生物标志物。
Cancer Cell. 2022 Nov 14;40(11):1358-1373.e8. doi: 10.1016/j.ccell.2022.10.017.
8
Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma.高危冒烟型骨髓瘤患者的基线突变模式与持续微小残留病阴性
Blood Adv. 2017 Sep 29;1(22):1911-1918. doi: 10.1182/bloodadvances.2017005934. eCollection 2017 Oct 10.
9
Real-world characteristics and outcomes of patients with high-risk and non-high-risk smoldering multiple myeloma using the Flatiron Health database.利用Flatiron Health数据库分析高危和非高危冒烟型多发性骨髓瘤患者的真实世界特征及预后
Blood Cancer J. 2024 Dec 5;14(1):215. doi: 10.1038/s41408-024-01170-z.
10
Early Intervention With a Curative Intent Through an Intensive Therapy Versus Immunologic Disease Control Using a Minimal Intensity Approach in the Management of High-risk Smoldering Multiple Myeloma: A Systematic Review of Evidence From Clinical Trials.高危冒烟型多发性骨髓瘤治疗中采用强化治疗（有治愈意向的早期干预）与采用最低强度治疗方案（免疫疾病控制）的对比：来自临床试验的证据的系统评价。
Clin Lymphoma Myeloma Leuk. 2023 Jan;23(1):e27-e40. doi: 10.1016/j.clml.2022.10.009. Epub 2022 Oct 23.

引用本文的文献

1
Contextualizing results of randomized trials in smoldering myeloma.解读冒烟型骨髓瘤随机试验的结果
Oncologist. 2025 Sep 1;30(9). doi: 10.1093/oncolo/oyaf216.
2
Observation or treatment for smoldering multiple myeloma? A systematic review and meta-analysis of randomized controlled studies.无症状多发性骨髓瘤的观察或治疗？一项随机对照研究的系统评价和荟萃分析。
Blood Cancer J. 2025 May 26;15(1):104. doi: 10.1038/s41408-025-01312-x.

本文引用的文献

1
Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma.达雷妥尤单抗或高危冒烟型多发性骨髓瘤的主动监测
N Engl J Med. 2025 May 8;392(18):1777-1788. doi: 10.1056/NEJMoa2409029. Epub 2024 Dec 9.
2
Patterns of progression in a contemporary cohort of 447 patients with smoldering multiple myeloma.447例冒烟型多发性骨髓瘤当代队列患者的疾病进展模式。
Blood Cancer J. 2024 Oct 14;14(1):176. doi: 10.1038/s41408-024-01159-8.
3
Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance.
高危冒烟型骨髓瘤的治疗策略：卡非佐米、来那度胺和地塞米松（KRd）治疗后进行移植、KRd 巩固治疗和 Rd 维持治疗。
J Clin Oncol. 2024 Sep 20;42(27):3247-3256. doi: 10.1200/JCO.23.02771. Epub 2024 Jul 22.
4
Three-dimensional telomere profiling predicts risk of progression in smoldering multiple myeloma.端粒三维分析可预测冒烟型多发性骨髓瘤的进展风险。
Am J Hematol. 2024 Aug;99(8):1532-1539. doi: 10.1002/ajh.27364. Epub 2024 May 15.
5
Mode of progression in smoldering multiple myeloma: a study of 406 patients.冒烟型多发性骨髓瘤的进展模式：一项对 406 例患者的研究。
Blood Cancer J. 2024 Jan 17;14(1):9. doi: 10.1038/s41408-024-00980-5.
6
Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study.伴意义未明单克隆丙种球蛋白血症或冒烟型多发性骨髓瘤患者的个体化进展预测（PANGEA）：一项回顾性、多队列研究。
Lancet Haematol. 2023 Mar;10(3):e203-e212. doi: 10.1016/S2352-3026(22)00386-6.
7
Prevalence of smoldering multiple myeloma based on nationwide screening.基于全国性筛查的冒烟型多发性骨髓瘤患病率。
Nat Med. 2023 Feb;29(2):467-472. doi: 10.1038/s41591-022-02183-6. Epub 2023 Feb 6.
8
Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma.高危冒烟型骨髓瘤患者免疫治疗反应的免疫生物标志物。
Cancer Cell. 2022 Nov 14;40(11):1358-1373.e8. doi: 10.1016/j.ccell.2022.10.017.
9
Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma.循环肿瘤细胞和免疫细胞在冒烟型多发性骨髓瘤微创风险分层中的应用。
Clin Cancer Res. 2022 Nov 1;28(21):4771-4781. doi: 10.1158/1078-0432.CCR-22-1594.
10
Monoclonal proteinuria predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio ≥100.单克隆蛋白尿预测游离轻链比值≥100 的无症状多发性骨髓瘤的进展风险。
Leukemia. 2022 May;36(5):1429-1431. doi: 10.1038/s41375-022-01529-w. Epub 2022 Feb 21.